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ABSTRACT
Objective: To evaluate and compare the behavior of glyco-
saminoglycans (GAGs) in Dupuytren disease (DD). Metho-
ds: This is an experimental study with 23 patients diagno-
sed with DD. Tissue collected through fasciectomy with 
incision type Brunner or McCash were evaluated by electro-
phoresis for identification of GAGs. The quantification was 
carried out by immunofluorescence and dosage of proteins 
for different types of glycosaminoglycans. The results were 
expressed in percentage and statistically evaluated. Re-
sults: A significant increase was observed through eletro-
phoresis in GAGs, as compared to the control (p<0.05). 
Immunofluorescence of hyaluronic acid was reduced (23 
times) when compared to the control (p<0.0001). Conclu-
sion: An increase of sulfated GAGs in Dupuytren’s disease, 
mainly dermatan sulfate, was evident from our results, as 
well as a pronounced decrease of hyaluronic acid in the 
palmar aponeurosis from the same patients. Level of Evi-
dence III, Case-Control Study.
Keywords: Dupuytren contracture. Glycosaminoglycans. Pro-
teoglycans. Fascia.
Article received in 09/23/2015, approved in 11/23/2015.
INTRODUCTION
Dupuytren’s disease (DD) is a fibroproliferative disorder that 
can cause progressive and permanent flexion contracture of 
the fingers.1 It is a debilitating condition characterized by fibrotic 
strands with consequent thickening of the palmar fascia, due 
to excessive collagen thick fibers (I and III).1,2
In Dupuytren’s disease, the main cells involved are myofibro-
blasts. These cells have both fibroblasts and smooth muscle 
cell characteristics, possessing the ability to contract actively. 
Contractility of myofibroblasts may be affected by prostaglan-
dins, which are present in the nodes and, thus,influence the 
disease, as well as other growth factors and proteins invol-
ved in fibrotic processes do, such as glycosaminoglycans 
(GAGs), which are increased in pathological processes with 
such characteristics. This abnormal cellular behavior can lead 
to changes in the extracellular matrix (ECM) and, consequently, 
changes in the conjunctive tissue array.3,4
The extracellular space is often filled by so-called fibroconnective 
extracellular matrix components. It consists, in varying propor-
tions, of collagen, elastic fibers, proteoglycans (PGs), glycosa-
minoglycans (GAGs) and cellular elements, which are organi-
zed forming a network, which is partly responsible for the great 
morphological and functional diversity of the various tissues.5-7 
GAGs were initially called mucopolysaccharides. They differ from 
each other according to the type of hexamine and nitrogen free 
sugar, according to the degree of sulfation and the position in 
which they are sulfated. This variety results in the following GAGs: 
heparin, heparan sulfate (HS); chondroitin sulfate (CS); dermatan 
sulfate (DS); keratan sulfate (KS) and hyaluronic acid (HA).3,4 The 
GAGs, except for the HA, are synthesized as proteoglycans.5
Despite the advances in knowledge and research on the metabolism 
of GAGs, little is known about the changes occurring in Dupuytren’s 
disease and Carpal Tunnel Syndrome, as well as their levels under 
pathological conditions.3,6,7 The aim of this study was to evaluate and 
compare the behavior of GAGs in Dupuytren’s disease.
MATeRIAlS AND MeThODS
This is an experimental study, conducted at the Discipline 
of Hand and Upper Limb Surgery at the Department of Or-
thopedics and Traumatology, EPM,UNIFESP, from July 2005 
to September 2006. The present study included 23 patients 
diagnosed with DD, who signed a Free and Informed Con-
sent Term. As control group, samples of normal palmar apo-
neurosis were taken from patients undergoing carpal tunnel 
release. The project was approved by the Ethics Committee
(N° 48734315.2.0000.5505).
The inclusion criterion was patients with surgical indication for 
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DD.Individuals who had recurrence of the disease were exclu-
ded from the study.
Samples were collected through fasciectomy with Brunner type 
incisions (multiple “V”) or by McCash technique, also known as 
open palm technique,where healing occurs by secondary intention.
extraction and identification of sulfated glycosaminogly-
cans (GAGs) 
The tissues were washed in phosphate buffered saline (PBS) 
to remove excess glutaraldehyde and chopped in acetone. The 
obtained fragments were dehydrated and kept for 24h at 4°C. 
The ketone powder obtained was weighed individually. The 
extraction was performed for each tissue separately. The dry 
powder was subjected to proteolysis with 4 mg/ml maxatase 
in 50mM Tris-HCl buffer at 60°C, pH 8.0. A NaCl solution final 
concentration 1M was added to the remaining volume. Nucleic 
acids peptides were precipitated with 90% trichloroacetic acid 
at final concentration 10% in an ice bath. After precipitation, 
the material was centrifuged for 20 min and the supernatant 
collected. To the supernatant two volumes of methanol were 
added to precipitate the GAGs. Precipitation was performed at 
-20°C (18-24h). The material was centrifuged and the precipitate 
containing the GAGs  was rehydrated in distilled water at a ratio 
of 5 mg of acetone powder to 20 µL distilled water.8
The compounds were applied to 0.2 cm thick agarose gel 
sheets (0.6%) in0.05M 1,3-diaminopropane acetate buffer pH 
9.0. The electrophoresis was performed in a refrigerated box at 
4°C and 100 mV for about one hour or until the proper migration 
occurred, indicated by red cresol dye.
After the electrophoresis, the glycosaminoglycans were precipi-
tated into the gel with 0.1% cetavlon (cetyltrimethylammonium 
bromide) for at least 2h. After drying under heat and ventilation, 
the gel was stained with 0.1% toluidine blue solution in 1% 
acetic acid and 50% ethanol.
Glycosaminoglycans were identified by comparing the electro-
phoretic migration of sample with known and purified standards. 
These same patterns were used for the quantitative determina-
tion of the compounds by optical densitometry at 525 nm.
This is a fluorometric method for determining hyaluronic acid in 
biological fluids, using binding probes to HA.9 The probe is iso-
lated from bovine nasal cartilage and consists of globular agre-
cam (a proteoglycan formed by a protein backbone to which 
strands of keratan sulfate and chondroitin sulfate are attached) 
and HA-binding protein. The probe is stabilized in ELISA plates, 
like a capture antibody such as a biotinylated probe, working, 
in the latter case, as a labeled secondary antibody.
To the ELISA plate with the adsorbed probe 100 µL/well of 
standard HA solutions of various concentrations (0 to 500 g/L) 
diluted in 0.05 M Tris-HCl assay buffer pH 7.75 and 1% bovine 
serum albumin (Amersham Life Science Ltd., Buckinghamshire, 
England) were added, besides sample solutions obtained from 
the aponeuroses diluted in the same test buffer, in triplicates.
The palmar aponeurosis were fixed in 10% formaldehyde in 
PBS and then included in Tissue Tek at minus 20°C. Then, they 
were cut in 8µm slices on a cryostat and placed on slides for 
immunofluorescence analysis.
The slides, after washing and digestion, were incubated with the 
primary antibody (1:100 byglican and decorin). Thereafter, the 
slides were kept at room temperature for 2h and washed with PBS.
The slides were, then, incubated with the secondary antibody 
(anti-decorin conjugated with AlexaFluor-488 and anti-byglican 
conjugated with Alexa fluor-594) for 2h at room temperature. 
After this step, the slides were washed five times with PBS and 
then incubated with the second primary antibody (ß-TGF) for 
4h at room temperature and then washed and incubated with 
the second secondary antibody (anti-ß-TGF conjugated with 
Alexa-fluor-594) for 2h at room temperature.
Subsequently, the slides were washed with PBS, and nuclei iden-
tification was performed by incubation with 1: 1000 4,6-diamidino-
2-phenylindole, dihidrocloride (DAPI, Molecular Probes, Eugene, 
OR, USA). Finally, slides were mounted in Fluoromont G (2:1 in 
PBS) and analyzed on a laser scanning confocal microscope.
ReSUlTS
There was a greater expression of GAGs extracted from the 
aponeuroses compromised by Dupuytren’s disease in the elec-
trophoresis (Figure 1), when compared to the electrophoresis 
of control aponeuroses. (Figure 2)
Figure 1. Electrophoretic behavior of GAGs extracted from aponeurosis 
of Dupuytren’s disease patientsin PDA agarose buffer (patients 8 - 14). 
Patients
P       8          9     10       11    12    13      14            
CS -
DS -
HS -
OR -
CS: chondroitin sulfate; DS: dermatan sulfate; HS: heparan sulfate; OR: origin; 
S: standard.
Dupuytren
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Figure 2. Electrophoretic behavior of GAGs extracted from aponeurosis of 
control patients in PDA agarose buffer (patients 1 - 7).
Control
Patients
7          6       5      4           3       2          1        P 
CS -
DS -
HS -
OR -
CS: chondroitin sulfate; DS: dermatan sulfate; HS: heparan sulfate; OR: origin; 
S: standard.
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tissue.11 It was isolated from ECM of connective tissues which, 
together with collagen, elastin and other glycoproteins, plays an 
important role in maintaining the tissue’s structural integrity.12
The literature described four-fold increase of DS of the palmar 
aponeurosis in DD patients.12 We found a marked increase of DS 
concentration in aponeuroses samples of Dupuytren patients. 
This was the most prevalent GAG in all samples, however, in 
those from DD patients, dermatansulfate was increased twice.
Besides chondroitin sulfate, DS may be the main GAG associated 
to collagen, which is involved with this protein’s organization and 
fibrogenesis.13 Its function is possibly associated with the organi-
zation, deposition rate and maintenance of collagen fibers.14 DS
occurs in high concentrations in fibrous tissues rich in type I collagen.
Although the decrease of HA in the palmar fascia of patients with 
Dupuytren has been described, our study showed a much more 
significant reduction than the literature findings (23 times lower). 
Perhaps this is due to some differences between the literature 
and our work such as, for example, different sensitivity of the 
method used to quantify HA and the use of cadaver samples 
in other works.
Medical literature has described the rise of up to 11-fold the 
amount of chondroitin sulfate on the palmar aponeurosis of pa-
tients with Dupuytren.14,15 However, despite the higher amount 
of CS found in patients with Dupuytren than  in the control 
groupin our study, this difference was not significant, diverging 
from other studies showing its increase in neoplastic tissues 
and other diseases such as arthrosis and chondrosarcoma. 
This may be a consequence of different sample size and GAG 
extraction methodology.16,17
However, heparan sulfate, which is located in the plasma mem-
brane and the ECM18 and regulates interactions between cells 
and their environment, was slight increase in the Dupuytren 
Figure 3. (1 - 4): Confocal microscopy; 1: negative control; 2: immunola-
beling with anti-decorin polyclonal antibody; 3: immunolabeling with anti 
ß-TGF polyclonal antibody;4: overlap of images B and C; (5 - 8): immu-
nolabeling of control patient; 5: negative control; 6: immunolabeling with 
anti-decorin polyclonal antibody; 7: immunolabeling for the ECM using anti 
ß-TGF polyclonal antibody; 8: overlap of images B and C, the nucleus was 
detected with DAPI; (9 - 12): immunolabeling of Dupuytren patient; 9: ne-
gative control; 10: immunolabeling with DAPI-detected nucleus; 11: immu-
nolabeling with anti-byglican polyclonal antibody; 12: overlap of images B 
and C; (13 - 16): immunolabeling of control patient; 13: negative control; 
14: identification of nucleus detected with DAPI; 15 immunolabeling with 
anti-byglican polyclonal antibody;16: overlap of images B and C.
Regarding the amount of total GAG (mg/g of dry weight), we 
found statistically significant differences values between Du-
puytren and control samples (p <0.03), an increase of almost 
twice on Dupuytren samples.
Chondroitin sulfate (CS) was increased in Dupuytren samples, 
however, the difference was not statistically significant (p <0.06).
In contrast, the concentration of dermatan sulfate (DS) in the 
Dupuytren sample compared to the control group was signifi-
cantly increase (p <0.03). However, heparan sulfate (HS) was 
the GAG  found in the smallest concentration, and there was no 
difference between samples.
The amount of hyaluronic acid (HA) was significantly lower in 
Dupuytren samples (23-fold) when compared to control sam-
ples (p <0.0001).
Regarding the percentage distribution, the GAG  found in the 
highest concentration in both samples was DS, but the differ-
ence between the two groups was not statistically significant
(p <0.77). The second most prevalent GAG in the samples was 
CS, which also showed no statistically significant difference be-
tween samples (p <0.11). HS was found in small quantities in 
Dupuytren and control samples, and its percentage was similar 
in both groups regarding aponeuroses composition of (p <0.55).
As noted in Figure 2, aponeuroses from Dupuytren patients 
showed a marked increase of dermatan sulfate (DS) and a 
little more discreet chondroitin sulfate (CS) increase, as com-
pared to the control. (Figure 1) Due to this result, we inves-
tigated the behavior of extracellular matrix proteoglycans of
CS/DS (decorin and byglican), of these aponeuroses, in order 
to characterize these tissues’ matrix. ß-TGF was also analyzed, 
as it binds to decorin.
In figure 3 we observe an increase in decorin labeling in tissue 
of Dupuytren patient (1 - 4) as compared to the control (5 - 8). 
The labeling of ß-TGF in both tissues is shown in Figure 3-3 and 
3-7. Figures 3-4 and 3-8 show an overlap of decorin and ß-TGF, 
showing that anchoring of decorin in the extracellular matrix of 
the tissue occurs in the presence of ß-TGF. It is also possible 
to observe that these components have determined an edge 
marking for the analyzed tissue. The nucleus was visualized with 
DAPI (blue). In Figures 3, 9-12 and 13-16 we observe the im-
munostaining for byglican in control and Dupuytren tissues. It is 
possible to observe an increased expression of this proteoglycan 
in DD tissues (Figure 3, 9-12) as well as an edge arrangement. 
DISCUSSION
There are few studies relating Dupuytren’s disease with GAGs 
metabolism,6,7 but it is known that there are changes in the 
ECM due to this pathology, which contributes to conjunctive 
tissue arrangement.5
GAGs are important components of the extracellular 
matrix,locally secreted and organized into a network located 
on the cell surface. Until recently, it was believed that ECM of 
vertebrates served as an inert structure that stabilized the physi-
cal structure of tissues. It is now clear that the matrix plays much 
more active and complex role in regulating cell behavior, directly 
influencing differentiation, migration, adhesion, cell proliferation 
and modulation, among others.10
Dermatan sulfate is a GAG found in a wide variety of vertebrate 
tissues. It is widely distributed in the form of proteoglycans in 
many tissues such as cornea, sclera, skin, liver and spleen 
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samples, as also observed by other authors.7,15 Several eviden-
ces suggest that HS plays an important role in cell recognition 
and adhesion, growth control and angiogenesis.19
Histologically, Dupuytren’s disease, also known as palmar fibro-
matosis, presents a behavior common to some cancers, such as 
fibroblast proliferation,20 proliferative and invasive growth,besides 
relapse. Fibroblasts found in Dupuytren’s disease show in vitro 
properties similar to tumors’, such as chromosomal abnormalities 
and binding capacity to monoclonal antibodies.21
As shown in an earlier work,19 the percentage distribution of 
sulfated GAGs in both groups was similar, CS was found in the 
highest concentrationand HS and in lowest.
In samples of Dupuytren’s disease patients, we found all GAGs 
increased, but mostly CS and DS. Dermatan sulfate was incre-
ased almost twice in these samples. We do not know whether 
the increased quantity of those GAGs is related to decreased 
degradation or increased synthesis. The reports on this aspect 
are inconclusive, which is an important point to be studied.15
As a hypothesis, we suggest that Dupuytren’s disease has 
some tumor characteristics such as infiltrative and prolifera-
tive behavior, besides presenting relapse. The altered GAGs-
metabolism, such as increased CS and decreased HA also 
reinforce the idea of a tumor behavior, as noted by Wilbrand
et al.,21 whose study found that 24% of DD patients developed 
a malignant tumor even after surgical treatment. However, some 
aspects are still to be researched through the metabolism of 
GAGs associated with the tumor behavior of this disease. We 
believe it should be possible to find a serum marker based on 
change in GAGs metabolism.
CONClUSION
It was evident the increase of sulfated GAGs in Dupuytren’s 
disease, mainly dermatan sulfate, and a marked decrease of 
hyaluronic acid in the patients’ palmar aponeurosis.
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